Clinical Trial Update: Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301) [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of Sofpironium bromide in axillary hyperhidrosis has completed, with results posted in 2024. The trial identified as BBI-4000-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axillary Hyperhidrosis

Drugs mentioned

• Sofpironium bromide (Sofpironium bromide)

Snippet

Sponsor: Botanix Pharmaceuticals | Conditions: Axillary Hyperhidrosis | Phase 3 | Status: COMPLETED | Results posted: 2024-06-06